Depression and Alcohol Use Disorder: A Clinical Deep-Dive

Overview

Depression and alcohol use disorder (AUD) are two of the most common mental health conditions in the world — and they frequently occur together. When they do, the clinical picture becomes significantly more complex, the outcomes significantly worse, and the treatment decisions significantly harder.

The central questions clinicians face are not simply "does this person have depression?" and "does this person drink too much?" The harder questions are: Which came first? Is the depression a direct consequence of heavy drinking — and therefore likely to resolve with abstinence — or is it an independent disorder that requires its own treatment? And how do we treat both at the same time without letting one undermine the other?

This article synthesizes findings from a multi-expert panel discussion grounded in verified research. It is designed to be honest about what the evidence shows, what it does not show, and where clinical decisions must currently be made in the absence of strong data.

Epidemiology

The co-occurrence of AUD and major depressive disorder (MDD) is well-established across large epidemiological studies. A foundational meta-analysis found that the presence of either disorder roughly doubles the risk of developing the other, with pooled adjusted odds ratios ranging from 2.00 to 2.09 ^[1]. These numbers come from population-level data and represent one of the most replicated findings in psychiatric epidemiology.

The consequences of this comorbidity are not merely additive — they compound. A longitudinal cohort study found that adolescents with concurrent depression and AUD were dramatically more likely than peers with depression alone to experience, as adults: depressive episodes (aOR 5.33; 95% CI 2.22–12.83), suicidality (aOR 5.37; 95% CI 2.28–12.66), and persistent AUD (aOR 7.68; 95% CI 2.59–22.81) ^[2]. Notably, 34% of the adolescent comorbid group experienced both conditions again in adulthood, compared to only 7% of those with depression alone ^[2].

In primary care settings — where most people first seek help — the overlap is striking. Among patients screened in primary care, those who screen positive for depression show substantially higher rates of high-risk drinking than those who screen negative ^[3]. Among people already identified as high-risk drinkers, a positive depression screen was associated with a 69.8% versus 48.0% prevalence of probable AUD ^[3]. These numbers make a strong case for routine dual screening.

Women are more likely to present with comorbid depression as the primary complaint; men are more likely to present with externalizing behaviors. This gender difference has implications for how clinicians recognize and respond to the comorbidity, though the corpus has limited data on gender-specific treatment outcomes.

The Bidirectional Relationship

The relationship between depression and AUD runs in both directions — but the evidence suggests the directions are not equally weighted.

When AUD precedes depression: Alcohol is a central nervous system depressant. Heavy, sustained drinking disrupts sleep architecture, depletes serotonin and dopamine systems, damages social and occupational functioning, and creates a neurobiological environment that promotes depressive symptoms. A prospective population-based study confirmed this asymmetry: the risk of incident depression increased with both the recency and severity of AUD at baseline, but the converse — depression predicting new-onset AUD — was not observed at the same magnitude ^[4]. The most plausible causal direction, based on available evidence, runs from AUD to MDD ^[1].

When depression precedes AUD: Many people begin drinking heavily as a way to manage depressive symptoms — to blunt emotional pain, reduce social anxiety, or simply feel something other than numbness. This self-medication pattern is clinically familiar and experientially validated. Daily diary data show that within-person increases in felt depression stigma are associated with increased alcohol consumption and heavy drinking on the same day ^[5]. The shame of depression, in other words, can itself become a trigger for drinking.

The spiral: In practice, the sequence often matters less than the feedback loop. Drinking worsens depression; depression drives more drinking. Changes in alcohol risk categories over 11–24 months tracked corresponding shifts in depression screening scores, with increases in drinking risk linked to higher depression prevalence ^[6]. Inflammation may be one biological mechanism: high C-reactive protein (CRP) levels amplified depression prevalence by 13–22% across drinking levels, interacting significantly with alcohol use ^[7].

Alcohol-Induced vs. Independent Depression

This distinction is arguably the most important clinical decision point in managing this comorbidity — and one of the most difficult to make in real time.

The DSM-5 framework distinguishes between a substance/medication-induced depressive disorder (where depressive symptoms are a direct physiological consequence of alcohol use) and an independent major depressive disorder that exists alongside AUD. The practical implication is significant: if the depression is alcohol-induced, treating the drinking may resolve the depression. If the depression is independent, both conditions require their own targeted treatment.

What the evidence shows about abstinence and depression: A large individual patient data meta-analysis of acamprosate-controlled trials (n=3,354 across 11 studies) found that continuous abstinence was the single most important factor in depression remission. Depressed patients with AUD who achieved continuous abstinence were 7.58 times more likely to see their depression remit than those who did not ^[8]. This is a powerful finding. It directly supports the clinical practice of observing a period of abstinence before diagnosing independent MDD.

Trajectory heterogeneity during early abstinence: Not everyone's depression resolves with abstinence, and the pattern of resolution varies considerably. Research on early abstinence identified three distinct trajectory subgroups: a low group (approximately 70% of patients) showing rapid symptom resolution, a high group (approximately 24%) with slower decline, and a sustained group (approximately 5–6%) maintaining high depressive and anxiety symptoms throughout the observation period ^[8]. This heterogeneity is clinically critical. The majority of patients will improve substantially with abstinence alone — but a meaningful minority will not, and they need to be identified and treated differently.

The 4-week observation window: Clinical guidelines commonly suggest observing 2–4 weeks of abstinence before diagnosing independent MDD and initiating antidepressants. The corpus supports the principle of this approach ^{[8] [8]}, but contains no prospective RCT data on the optimal duration of observation, what threshold should trigger pharmacotherapy, or whether early antidepressant initiation causes harm. This is a significant evidence gap. Clinicians are currently making high-stakes prescribing decisions without evidence-based timing guidance.

Why the Sequence Matters

Getting the diagnosis right has direct treatment consequences.

For alcohol-induced depression, the primary intervention is treating the AUD. Abstinence is itself antidepressant for a substantial proportion of patients ^[8]. Initiating antidepressants prematurely may expose patients to medication side effects and drug-alcohol interactions without meaningful benefit — and may create a false sense that the depression is being addressed while the underlying drinking continues.

For independent MDD, both conditions require simultaneous, targeted treatment. Waiting for alcohol use to resolve before treating depression is not evidence-supported. Critically, the reverse assumption — that treating depression will secondarily reduce drinking — is also not supported. A randomized controlled trial of depression treatments (CBT, exercise, and treatment as usual) found that alcohol consumption patterns did not significantly change despite improvements in depression; AUDIT scores remained largely stable ^[2]. This is one of the most important corrective findings in the corpus: treating depression alone does not reliably reduce alcohol use.

Misdiagnosis in either direction carries real costs. Diagnosing alcohol-induced depression as independent MDD leads to unnecessary antidepressant exposure. Failing to diagnose independent MDD leaves a treatable condition untreated, sustains the depression-drinking feedback loop, and elevates suicide risk.

Antidepressant Evidence

The evidence base for antidepressants in comorbid AUD-MDD is more limited — and more mixed — than clinical practice guidelines sometimes suggest ^[9].

SSRIs: A network meta-analysis of 36 RCTs (n=2,729) found moderate confidence that SSRIs improve functional status (SMD = −0.92; 95% CI −1.36 to −0.47) and low confidence for a modest reduction in alcohol use (SMD = −0.30; 95% CI −0.59 to −0.02). However, SSRIs were also associated with moderate confidence of increased adverse events (OR = 2.20; 95% CI 0.94 to 5.16) ^[9] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). For the primary outcomes — remission from depression and remission from AUD — the authors explicitly reported very low confidence in all estimates ^[9].

TCAs (tricyclic antidepressants): Low-confidence evidence of modest depressive symptom reduction (SMD = −0.37; 95% CI −0.72 to −0.02) ^[9]. TCAs carry additional safety concerns in patients who are actively drinking, including cardiac effects and overdose risk.

Sertraline + naltrexone (the Pettinati model): The clinical review by Bahji et al. describes a case example in which sertraline plus naltrexone plus CBT produced significant improvements in both mood and alcohol use ^[8]. This combination — targeting both the serotonin system and the opioid reward pathway — reflects the theoretical rationale for dual pharmacotherapy. However, this is a narrative clinical review and a single case illustration, not a controlled trial, and should be interpreted accordingly. The evidence for this combination is directionally promising but not yet established at the level of a meta-analysis.

The honest bottom line on antidepressants: SSRIs and TCAs are reasonable options for treating independent MDD in patients with AUD, but clinicians should not expect antidepressants alone to meaningfully reduce alcohol consumption ^[2]. Evidence on differential antidepressant response by depression subtype (alcohol-induced vs. independent), SSRI-alcohol pharmacokinetic interactions, and hepatotoxicity monitoring thresholds is currently limited in the published literature. These are real clinical gaps.

Combining Antidepressants with AUD Pharmacotherapy

The strongest clinical rationale in this corpus is for treating both axes simultaneously rather than sequentially.

Naltrexone (an opioid antagonist that reduces alcohol craving and reward) and acamprosate (which stabilizes glutamate signaling disrupted by chronic alcohol use) are first-line AUD medications ^[8]. Both can be used alongside antidepressants. The acamprosate data are particularly instructive: the medication's effect on supporting abstinence was consistent across both depressed and non-depressed patients — but depressed patients had lower motivation and compliance at treatment initiation ^[8]. This suggests that depression itself is a barrier to AUD treatment engagement, reinforcing the need to address both conditions.

The combination principle: Bahji et al. assert that combining antidepressants with AUD medications improves treatment efficacy ^[8]. This is a clinical guidance statement, not a finding from a head-to-head RCT. The Grant et al. network meta-analysis found that no single intervention produced superior outcomes on both depression and alcohol use simultaneously ^[9]. These two claims are not directly contradictory — Bahji et al. compare integrated care to the status quo, while Grant et al. compare active treatments against each other — but the tension is real and should temper overconfidence in any specific combination.

The reconciliation: Integrated approaches are conceptually superior and directionally supported by the evidence. The Riper et al. meta-analysis found that combined CBT and motivational interviewing produced small but statistically significant effects for both alcohol reduction (g=0.17) and depression symptom reduction (g=0.27) compared to usual care ^[10]. Small effects are still real effects, particularly when the alternative is treating only one condition and watching the other persist. The honest synthesis is that integrated pharmacotherapy plus psychotherapy outperforms single-axis treatment — but the optimal specific combination has not been established.

Behavioral Treatments

Psychotherapy is a central pillar of treatment for this comorbidity, and in some respects has a stronger evidence base than pharmacotherapy for the dual-diagnosis population.

CBT for depression (CBT-D): The network meta-analysis found moderate confidence that CBTs demonstrated greater benefit than no additional treatment for depressive symptoms (SMD = −0.84; 95% CI −1.05 to −0.63), with low confidence for alcohol use reduction ^[9]. The confidence rating for CBT's depression outcomes is meaningfully higher than for any pharmacological intervention in the corpus.

Behavioral activation (BA): BA — which focuses on re-engaging people with rewarding activities, reducing avoidance, and rebuilding structure — is particularly relevant in early recovery. Clinical reviews suggest that behavioral activation may be effective in treating depression while also reducing alcohol cravings, though RCT evidence specific to the AUD-depression comorbid population is currently limited ^[8]. This dual mechanism matters: in early abstinence, anhedonia (the inability to feel pleasure) is both a depression symptom and a relapse trigger. Structured activity scheduling directly counters the withdrawal-related flatness that can drive people back to drinking.

An important caveat for early recovery: Cognitive impairment affects a substantial proportion of early-detoxified AUD patients across neuropsychological domains (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). This has direct implications for therapy delivery. Cognitively demanding components of CBT — thought records, cognitive restructuring, Socratic questioning — may be poorly tolerated in the first weeks of abstinence. Behavioral activation, which places lower cognitive demands, may be a more appropriate starting point before more complex cognitive work is introduced.

Combined CBT and motivational interviewing (MI): The Riper et al. meta-analysis found that this combination produced small but clinically significant effects for both alcohol reduction (g=0.17) and depression symptom reduction (g=0.27) ^[10]. MI addresses ambivalence about change — a particularly important target in a population where depression reduces motivation and AUD creates its own psychological defenses against treatment.

What the corpus cannot tell us: There are no RCTs specifically examining behavioral activation protocols adapted for AUD-depression comorbidity. The evidence base for CBT-D adaptations specific to AUD is largely inferred from general CBT trials. The corpus also cannot answer what the optimal timing and sequencing of CBT-D components should be relative to abstinence duration — a clinically critical gap.

Sleep

Insomnia sits at the intersection of depression, AUD, and relapse risk — and deserves explicit clinical attention.

Alcohol disrupts sleep architecture, suppressing REM sleep and causing rebound insomnia during withdrawal. Depression independently causes insomnia and hypersomnia. In early recovery, sleep disturbance is both a withdrawal symptom and a depression symptom — and a well-documented trigger for relapse. Patients who cannot sleep are at elevated risk of returning to alcohol as a sleep aid.

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for insomnia in this population. It addresses the behavioral and cognitive patterns that perpetuate sleeplessness without the risks associated with pharmacological sleep aids.

Benzodiazepines and Z-drugs (such as zolpidem) should be avoided for sleep management in patients with AUD. Both carry significant addiction potential, and benzodiazepines in particular have cross-tolerance with alcohol, creating risks of dependence substitution and dangerous interactions. The corpus does not provide specific pharmacological alternatives for sleep in this population beyond the CBT-I recommendation — a gap that clinicians managing withdrawal-related insomnia will feel acutely.

Suicide Risk

The combination of depression, AUD, and acute intoxication represents one of the highest-risk clinical scenarios in psychiatry.

Alcohol lowers inhibition, impairs judgment, and intensifies emotional pain — all of which increase the likelihood that suicidal ideation will translate into suicidal behavior. The longitudinal data are unambiguous: adolescents with concurrent depression and AUD were 5.37 times more likely (95% CI 2.28–12.66) to experience suicidality as adults compared to peers without this comorbidity ^[2]. Alcohol dependence can exacerbate psychiatric symptoms and increase suicide risk in this population ^[11].

Care transition windows are highest-risk. The period immediately following detoxification, hospital discharge, or residential treatment completion is when patients are most vulnerable. They have lost the structure of an inpatient or intensive outpatient setting, may be returning to environments associated with drinking, and may experience a resurgence of depressive symptoms as the neurobiological effects of alcohol withdrawal evolve. Explicit safety planning, warm handoffs to outpatient care, and close follow-up in the first weeks after any care transition are essential.

Stigma as a risk amplifier: Daily diary data show that within-person increases in felt depression stigma are associated with same-day increases in alcohol consumption and heavy drinking ^[5]. Shame about depression can drive drinking, which in turn elevates suicide risk. Addressing stigma — explicitly, in treatment — is not a soft clinical goal. It is a safety intervention.

Gender Differences

Women are more likely to present with comorbid depression as the primary complaint; men are more likely to present with externalizing behaviors, conduct problems, or AUD as the presenting issue. This means that women's AUD may be underrecognized when depression is the chief complaint, and men's depression may be underrecognized when AUD is the presenting problem.

The corpus acknowledges the importance of gender-sensitive interventions but contains insufficient research on how gender differences affect treatment outcomes in comorbid AUD-MDD populations ^[2]. A pilot study of integrated treatment for depression and AUD showed promising results in reducing symptom severity and improving patient satisfaction ^[12], but involved only seven women — far too small a sample to draw generalizable conclusions. This is a meaningful gap in the evidence base.

Primary Care and Collaborative Care

Most people with depression and AUD do not first present to a psychiatrist or addiction specialist. They present to a primary care physician, a nurse practitioner, or an emergency department. This makes primary care the front line of identification — and a critical leverage point for intervention.

The screening gap is real. Patients with depression are systematically under-screened for AUD in primary care ^[3] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). Given that patients with positive depression screens show substantially higher rates of high-risk drinking ^[3], the case for routine dual screening — PHQ-9 for depression and AUDIT-C for alcohol use — is strong and evidence-supported.

Collaborative care models — in which a psychiatrist or behavioral health consultant works alongside a care manager embedded in primary care — represent the most scalable approach to integrated treatment. These models improve outcomes for depression in primary care settings and are well-suited to the dual-diagnosis population, where the complexity of managing two interacting conditions exceeds what a single primary care visit can address. The corpus supports integrated treatment as superior to sequential approaches ^[8], and collaborative care is the implementation model most likely to deliver that integration at scale.

Older Adults

Depression-AUD comorbidity in older adults is underrecognized and undertreated. Older adults may present with atypical depressive symptoms — fatigue, cognitive complaints, somatic concerns — rather than classic low mood. Alcohol use may be minimized or normalized as a social behavior. Screening tools calibrated for younger adults may miss the pattern.

Polypharmacy is a significant concern. Older adults are more likely to be taking multiple medications, and the interactions between antidepressants, AUD medications, and other drugs (anticoagulants, antihypertensives, analgesics) require careful management. The corpus does not provide specific guidance on pharmacotherapy in older adults with this comorbidity — a gap that reflects a broader underrepresentation of older adults in psychiatric RCTs.

Veterans

Veterans represent a population with disproportionately high rates of AUD, depression, and PTSD — and the triple comorbidity of PTSD-MDD-AUD is common and particularly difficult to treat. The VA/DoD Clinical Practice Guidelines address depression-AUD comorbidity, and the VA system has invested in integrated care models. However, the corpus does not contain specific VA/DoD CPG data, and the evidence base for treating the triple comorbidity remains limited.

Trauma history is a critical contextual factor. For veterans whose depression and AUD are both downstream of PTSD, treating depression and AUD without addressing the underlying trauma is unlikely to produce durable recovery. Trauma-focused therapies (Prolonged Exposure, Cognitive Processing Therapy) may need to be integrated into the treatment plan — though the sequencing of trauma work relative to AUD stabilization remains an area of clinical debate and limited evidence.

Ketamine and Emerging Treatments

Ketamine — specifically esketamine (Spravato), FDA-approved for treatment-resistant depression — has generated significant interest as a rapidly acting antidepressant. For patients with treatment-resistant depression and comorbid AUD, ketamine's rapid onset could theoretically interrupt the depression-drinking spiral more quickly than traditional antidepressants. However, ketamine itself carries addiction potential, and its use in patients with active AUD raises legitimate safety concerns. The evidence base for ketamine in comorbid AUD-MDD is currently limited and in active research. The corpus does not contain RCT-level data on this combination.

Psychedelic-assisted therapy (psilocybin, MDMA) is in early research stages for both depression and AUD separately, with some preliminary evidence of benefit for each condition. Whether these approaches will prove safe and effective for the comorbid population is unknown. Clinicians should be aware that patients may ask about these treatments, and honest communication about the current state of evidence — promising but preliminary — is appropriate.

Evidence Gaps

Honest acknowledgment of what the evidence cannot yet tell us is essential for clinical integrity.

The following gaps were identified across the expert panel:

Timing of antidepressant initiation: The corpus contains no prospective RCT data on when to initiate antidepressants after abstinence begins, what duration of observation is sufficient to distinguish alcohol-induced from independent depression, or whether early initiation causes harm. This is the most consequential gap for day-to-day prescribing decisions.

Head-to-head AUD pharmacotherapy comparisons in dual-diagnosis patients: No corpus document compares naltrexone versus acamprosate specifically in patients with comorbid MDD, stratified by depression subtype ^[8]. Clinicians choosing between these agents in dual-diagnosis patients are doing so without comparative evidence.

Behavioral activation RCTs for AUD-depression comorbidity: There are no RCTs specifically examining behavioral activation protocols adapted for this population. The evidence is largely inferred from general CBT trials.

Long-term outcomes: Most studies in this corpus examine outcomes at post-treatment or short-term follow-up. Long-term integrated-care outcomes beyond 12 months are largely absent.

Peer support and mutual aid: No document examines peer-support or mutual-aid delivery models within integrated care — a significant gap given that many people first encounter help through recovery communities rather than specialty clinics.

Gender-specific treatment outcomes: The corpus acknowledges gender differences in presentation but contains insufficient data on differential treatment response by gender.

Socioeconomic and cultural factors: The mechanisms by which socioeconomic status, microaggressions, and cultural context modify the depression-AUD relationship are underexplored ^{[13] [4]}.

Summary: What the Evidence Supports

The evidence is clear on the principle of integrated, simultaneous treatment. It is far less clear on the specifics of which medications, in what combination, initiated at what point in the abstinence timeline, will produce the best outcomes for which patients. That gap between principle and practice is where most clinical decisions currently live — and where the next generation of research needs to go.

Verified References

• ^[11] Abid-Chapon, Nelly, Rasho, Abdul Rahman, Delouvée, Sylvain (2025). "Preventing Suicide Among Alcohol-Dependent Women: A Scoping Review of Clinical and Socio-Cultural Factors.". Subst Use Misuse. DOI: 10.1080/10826084.2025.2478605 [abstract-verified: yes]
• ^[8] Bahji, Anees, Tang, Victor, Danilewitz, Marlon (2025). "Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders.". Can J Psychiatry. DOI: 10.1177/07067437251374564 [abstract-verified: partial]
• ^[1] Joseph M Boden, David M Fergusson (2011). "Alcohol and depression.". Addiction (Abingdon, England). DOI: 10.1111/j.1360-0443.2010.03351.x [abstract-verified: yes]
• ^[2] Bohman, Hannes, Låftman, Sara Brolin, Alaie, Iman et al. (2025). "Adult mental health outcomes of adolescent depression and co-occurring alcohol use disorder: a longitudinal cohort study.". Eur Child Adolesc Psychiatry. DOI: 10.1007/s00787-024-02596-3 [abstract-verified: partial]
• ^[13] Cavazos-Rehg, Patricia A, Li, Xiao, Paraboschi, Layna et al. (2025). "Associations between microaggressions, depression, anxiety, and alcohol use among Black young adults: findings from a pilot study.". Front Public Health. DOI: 10.3389/fpubh.2025.1694000 [abstract-verified: partial]
• ^[14] Funderburk, Jennifer S, Possemato, Kyle, Maisto, Stephen A (2013). "Differences in what happens after you screen positive for depression versus hazardous alcohol use.". Mil Med. DOI: 10.7205/milmed-d-13-00165 [abstract-verified: partial]
• ^[8] Gopaldas, Manesh, Flook, Elizabeth A, Hayes, Nick et al. (2025). "Subgroups of anxiety and depression trajectories during early abstinence in alcohol use disorder.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.70032 [abstract-verified: partial]
• ^[9] Grant, Sean, Azhar, Gulrez, Han, Eugeniu et al. (2021). "Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis.". PLoS Med. DOI: 10.1371/journal.pmed.1003822 [abstract-verified: partial]
• ^[6] Hallgren, Kevin A, Jack, Helen E, Oliver, Malia et al. (2023). "Changes in alcohol consumption reported on routine healthcare screenings are associated with changes in depression symptoms.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.15075 [abstract-verified: yes]
• ^[4] Lasserre, Aurélie M, Imtiaz, Sameer, Roerecke, Michael et al. (2022). "Socioeconomic status, alcohol use disorders, and depression: A population-based study.". J Affect Disord. DOI: 10.1016/j.jad.2021.12.132 [abstract-verified: partial]
• ^[8] Lejoyeux, Michel, Lehert, Philippe (2011). "Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies.". Alcohol Alcohol. DOI: 10.1093/alcalc/agq077 [abstract-verified: yes]
• ^[12] Persson, Anna, Finn, Daniel Wallhed, Broberg, Alice et al. (2025). "Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol use disorder care - a pilot study.". Front Psychiatry. DOI: 10.3389/fpsyt.2025.1473988 [abstract-verified: partial]
• ^[10] Heleen Riper, Gerhard Andersson, Sarah B Hunter et al. (2014). "Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis.". Addiction (Abingdon, England). DOI: 10.1111/add.12441 [abstract-verified: yes]
• ^[7] Rita-Venugopal, Lekshmi, Varghese M, Tom, Kc, Madhav (2026). "Association between C-reactive protein and depression among alcohol users in the United States: A population-based analysis of National Health and Nutrition Examination Survey (NHANES) 2015-2020.". J Psychiatr Res. DOI: 10.1016/j.jpsychires.2026.02.009 [abstract-verified: yes]
• ^[3] Ryan, Emma D, Chang, Yanni M, Oliver, Malia et al. (2022). "An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive for depression and high-risk drinking.". BMC Health Serv Res. DOI: 10.1186/s12913-022-08408-1 [abstract-verified: yes]
• ^[2] Strid, Catharina, Hallgren, Mats, Forsell, Yvonne et al. (2019). "Changes in alcohol consumption after treatment for depression: a secondary analysis of the Swedish randomised controlled study REGASSA.". BMJ Open. DOI: 10.1136/bmjopen-2018-028236 [abstract-verified: partial]
• ^[5] Wang, Katie, Manning, Robert B, Weiss, Nicole H et al. (2026). "Depression stigma and alcohol use among adults with major depressive disorder: a daily diary study.". Addict Behav. DOI: 10.1016/j.addbeh.2026.108737 [abstract-verified: yes]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[15] → ^[2] (verifier: partial; score 0.85). Title: Treatment of the depressed alcoholic patient.
• ^[15] → ^[16] (verifier: partial; score 0.74). Title: Motivation to change and posttreatment temptation to drink: a multicenter study among alcohol-dependent patients.
• ^[17] → ^[3] (verifier: partial; score 0.75). Title: Factors that facilitate treatment uptake for women with alcohol use disorders in high-income countries: A systematic rev
• ^[18] → ^[4] (verifier: partial; score 0.76). Title: Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-releas
• ^[19] → ^[8] (verifier: partial; score 0.77). Title: Subgroups of anxiety and depression trajectories during early abstinence in alcohol use disorder.
• ^[8] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[20] → ^[8] (verifier: partial; score 0.77). Title: Subgroups of anxiety and depression trajectories during early abstinence in alcohol use disorder.
• ^[20] → ^[4] (verifier: partial; score 0.85). Title: Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-releas
• ^[20] → ^[2] (verifier: partial; score 0.81). Title: Treatment of the depressed alcoholic patient.
• ^[20] → ^[21] (verifier: partial; score 0.82). Title: Perspectives on the Implementation of Screening and Treatment for Depression and Alcohol Use Disorder in Primary Care in
• ^[22] → ^[2] (verifier: partial; score 0.71). Title: Treatment of the depressed alcoholic patient.
• ^[22] → ^[23] (verifier: partial; score 0.69). Title: Species differences in comorbid alcohol use disorder and major depressive disorder: A narrative review.
• ^[24] → ^[9] (verifier: partial; score 0.82). Title: Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.
• ^[24] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[25] → ^[14] (verifier: partial; score 0.74). Title: Concurrent Treatment of Posttraumatic Stress Disorder and Alcohol Use Disorder in Women: A Randomized Clinical Trial.